PT  - JOURNAL ARTICLE
AU  - Bennuru, Sasisekhar
AU  - Kodua, Frimpong
AU  - Dahlstrom, Eric
AU  - Nutman, Thomas B
TI  - Improved NAAT assay for the diagnosis of onchocerciasis and its use for detection of circulating cell free DNA
AID  - 10.1101/2023.09.13.23295358
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.13.23295358
4099  - http://medrxiv.org/content/early/2023/09/15/2023.09.13.23295358.short
4100  - http://medrxiv.org/content/early/2023/09/15/2023.09.13.23295358.full
AB  - Mass drug administration (MDA) programs aimed at control and elimination of onchocerciasis relies on annual or semi-annual distribution of Ivermectin (IVM) that target the microfialarial (mf) stage of the parasite Onchocerca volvulus. The co-endemicity of onchocerciasis with other filarial species often leads to interruptions in the control programs. A much-needed tool for the elimination efforts are sensitive diagnostic assays that can help differentiate from other co-endemic filarial infections or xenomonitoring approaches. qPCR assays targeting highly repeated elements in the genomes have allowed for increased sensitivity of detection that are pathogen-specific. Utilizing NGS data, qPCR assays were designed to target 15 highly repeated targets from O. volvulus and 11 from O. ochengi. The two most sensitive and specific repeats Ov15R and Ov16R from O. volvulus and OoR1 and OoR5 from O. ochengi, were selected for further testing.The analytical sensitivity of both Ov15R and Ov16R were similar with limits of detection (LOD) at 1 fg of O. volvulus genomic DNA (gDNA), and 100% specificity and ∼32-fold sensitive than O-150 qPCR. Similarly, OoR1 and OoR5 had LOD of 100 fg of O. ochengi gDNA. Using DNA obtained previously from skin snips, Ov16R identified 17 additional samples as positive for infections when compared to O-150.Further, to eliminate the need for time-dependent sample acquisition, we evaluated the efficiency of plasma-derived circulating cell-free DNA (ccfDNA) to detect O. volvulus infections and as a potential modality for testing cure of infection. Plasma-derived ccfDNA failed to amplify Ov16R. In contrast using a small set of urine-derived ccfDNA samples from Ov-infected individuals had varying levels of detectability as early as 12-24 hours post-treatment. To enable processing of larger volumes of urine for better sensitivity, a modified chitosan-based filter technique was developed as proof-of-concept that efficiently captured gDNA from 1-15ml of urine.Interestingly, Ov15R, Ov16R and O-150 map to the same contigs of O. volvulus genome. This prompted the redesign of O-150 qPCR that resulted in O-150-New qPCR assay that performs on par with Ov15R/Ov16R, thus offering more sensitive and specific diagnosis of O. volvulus that can easily be configured to field-friendly formats such as LAMP or RPA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by the Division of Intramural Research (DIR) of the National Institute of Allergy and Infectious Diseases, NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All archived serum/plasma or urine samples were obtained as part of National Institute of Allergy and Infectious Diseases Institutional Review Board-approved protocols for filaria-infected patients (NCT00001230) and healthy donors (NCT00090662). As part of routine clinical care, informed written consent was obtained from all subjects. Archived DNA samples from skin snips were from previous studies (Nana-Djeunga HC et.al., 2019 Clin Inf Dis, that received ethical clearance from the Cameroon National Ethics Committee for Research in Human Health (No. 2013/11/370/L/CNERSH/SP), and an administrative authorization was granted by the Ministry of Public Health (D30- 571/L/MINSANTE/SG/DROS/CRSPE/BBM). All eligible volunteers signed an informed consent form for their participation in the study, including for the further use of their samples.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript